Cesario A S, Palermo P, Baragli D, Amici E, Biancalana G, Gambelli G, Neri R
Divisione di Cardiologia, Ospedale G.B. Grassi, Roma.
G Ital Cardiol. 1998 Aug;28(8):878-86.
Potentially lethal interactions between concomitantly implanted pacemaker and automatic first-generation cardioverter-defibrillator have been reported. We therefore evaluated the reliability and safety of simultaneous implantation of dual-chamber pacemakers with a fourth generation cardioverter-defibrillator incorporating an improved arrhythmia detection system.
Concomitant implantation of an automatic cardioverter defibrillator and a dual-chamber pacemaker was performed in four patients for malignant tachyarrhythmias and symptomatic bradycardia. Two Jewel 7219C and two Micro Jewel 7223 (Medtronic Inc.) implantable cardioverter defibrillators were connected to an endocardial lead (Medtronic Mod. 6936). In 2 patients with a previously implanted cardioverter-defibrillator, the pacemaker was connected to bipolar atrial and ventricular leads. In the 2 patients who already had a dual-chamber pacemaker, the unipolar pacing leads implanted previously were used. At the time of implantation of the second device, interaction testing was performed evaluating ventricular fibrillation detection during high-output asynchronous pacing. Testing for malfunctions, reprogramming or variations of pacing thresholds of the pacemakers after electric shocks was also carried out. Moreover, intracavitary signals, stimulation thresholds and electrical therapies delivered were evaluated during follow-up.
During interaction testing, induced ventricular fibrillation was detected, with no delay, in 4/4 cases (100%). After a mean follow-up of 6.3 +/- 5 months (range 2-13), 5 shocks for ventricular fibrillation, 10 shocks for fast ventricular tachycardia and 72 antitachycardia pacings were delivered. All these electrical therapies were considered appropriate. No symptomatic sustained tachyarrhythmia remained undetected.
These data suggest that concomitant implantation of a fourth-generation automatic cardioverter-defibrillator and a dual-chamber pacemaker using either unipolar or bipolar leads can be performed safely. Extreme caution and rigorous interactions testing is nevertheless advised when considering this device combination.
已有报道指出,同期植入的起搏器与第一代自动心脏复律除颤器之间可能存在致命性相互作用。因此,我们评估了同时植入具有改进心律失常检测系统的双腔起搏器与第四代心脏复律除颤器的可靠性和安全性。
对4例患有恶性快速心律失常和症状性心动过缓的患者同时植入自动心脏复律除颤器和双腔起搏器。两台Jewel 7219C和两台Micro Jewel 7223(美敦力公司)植入式心脏复律除颤器与一根心内膜导线(美敦力型号6936)相连。在2例先前已植入心脏复律除颤器的患者中,起搏器与双极心房和心室导线相连。在另外2例已植入双腔起搏器的患者中,使用先前植入的单极起搏导线。在植入第二个设备时,进行了相互作用测试,评估高输出异步起搏期间的心室颤动检测情况。还对电击后起搏器的故障、重新编程或起搏阈值变化进行了测试。此外,在随访期间评估了心腔内信号、刺激阈值和所给予的电治疗。
在相互作用测试期间,4/4例(100%)均能立即检测到诱发性心室颤动。平均随访6.3±5个月(范围2 - 13个月)后,共进行了5次心室颤动电击、10次快速室性心动过速电击和72次抗心动过速起搏。所有这些电治疗均被认为是恰当的。未漏诊有症状的持续性快速心律失常。
这些数据表明,使用单极或双极导线同时植入第四代自动心脏复律除颤器和双腔起搏器是安全可行的。然而,在考虑这种设备组合时,建议极度谨慎并进行严格的相互作用测试。